Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer
暂无分享,去创建一个
Jennifer B Dennison | S. Demo | M. Bennett | F. Parlati | T. Chernov-Rogan | Taotao Wang | A. Mackinnon | E. Lewis | Jinfu Yang | P. Shwonek | Matt I. Gross | Guy J. Laidig | F. Zhao | J. Janes | Lijing Chen | Mirna L. M. Rodriguez | B. Goyal | E. Sjogren | Jim Li | Timothy F. Stanton | J. Dennison
[1] N. Sang,et al. ErbB2 Activation Upregulates Glutaminase 1 Expression Which Promotes Breast Cancer Cell Proliferation , 2014, Journal of cellular biochemistry.
[2] J. Gray,et al. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. , 2013, Cancer cell.
[3] Ralph J DeBerardinis,et al. Glutamine and cancer: cell biology, physiology, and clinical opportunities. , 2013, The Journal of clinical investigation.
[4] G. Stephanopoulos,et al. In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. , 2013, Cell metabolism.
[5] John M. Asara,et al. Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway , 2013, Nature.
[6] C. Dang,et al. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. , 2012, Journal of medicinal chemistry.
[7] N. Curthoys,et al. BPTES inhibition of hGA124–551, a truncated form of human kidney-type glutaminase , 2012, Journal of enzyme inhibition and medicinal chemistry.
[8] K. Bachman,et al. Analysis of glutamine dependency in non-small cell lung cancer , 2012, Cancer biology & therapy.
[9] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[10] K. Thangavelu,et al. Structural basis for the allosteric inhibitory mechanism of human kidney-type glutaminase (KGA) and its regulation by Raf-Mek-Erk signaling in cancer cell metabolism , 2012, Proceedings of the National Academy of Sciences.
[11] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[12] T. Fan,et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. , 2012, Cell metabolism.
[13] A. Cassago,et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism , 2012, Proceedings of the National Academy of Sciences.
[14] Takashi Tsukamoto,et al. Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. , 2012, Cell metabolism.
[15] Abhishek K. Jha,et al. Full-length human glutaminase in complex with an allosteric inhibitor. , 2011, Biochemistry.
[16] J. Chi,et al. Glutamine Synthetase Is a Genetic Determinant of Cell Type–Specific Glutamine Independence in Breast Epithelia , 2011, PLoS genetics.
[17] C. Dang,et al. Otto Warburg's contributions to current concepts of cancer metabolism , 2011, Nature Reviews Cancer.
[18] R. Deberardinis,et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells , 2011, Proceedings of the National Academy of Sciences.
[19] G. Riggins,et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. , 2010, Cancer research.
[20] C. Dang,et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. , 2010, Cancer cell.
[21] C. Thompson,et al. Glutamine addiction: a new therapeutic target in cancer. , 2010, Trends in biochemical sciences.
[22] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[23] N. Curthoys,et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). , 2007, The Biochemical journal.
[24] Wen-Lin Kuo,et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.
[25] Jorma Isola,et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. , 2004, Molecular cancer therapeutics.
[26] D. V. Von Hoff,et al. Azaserine, DON, and azotomycin: three diazo analogs of L-glutamine with clinical antitumor activity. , 1979, Cancer treatment reports.
[27] H. Krebs. Metabolism of amino-acids: The synthesis of glutamine from glutamic acid and ammonia, and the enzymic hydrolysis of glutamine in animal tissues. , 1935, The Biochemical journal.
[28] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[29] Tsung-Cheng Chang,et al. c-Myc suppression of miR-23 a / b enhances mitochondrial glutaminase expression and glutamine metabolism , 2009 .
[30] S. Bannai,et al. Role of membrane transport in metabolism and function of glutathione in mammals , 2005, The Journal of Membrane Biology.
[31] M. Watford,et al. Regulation of glutaminase activity and glutamine metabolism. , 1995, Annual review of nutrition.
[32] F. Muggia,et al. The rediscovery of DON (6-diazo-5-oxo-L-norleucine). , 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.